Why is Cohance Life falling/rising?

As of 19-Sep, Cohance Lifesciences Ltd is experiencing a decline in its stock price, currently at 909.45, reflecting a decrease of 4.7 points or 0.51%. The stock has been underperforming, having fallen consecutively for the last three days, resulting in a total decline of 8.1% during this period. Today's performance indicates that it has underperformed its sector by 0.78%. Over the past week, the stock has decreased by 6.70%, and year-to-date, it has seen a significant drop of 19.76%. Despite a high management efficiency indicated by a return on equity (ROE) of 24.14% and a low debt-to-equity ratio, the company faces challenges such as poor long-term growth, with operating profit growing at only 2.95% annually over the last five years, and a substantial decline in profit after tax of 41.1% compared to previous quarters.
Broader market context shows that while the Sensex has gained 0.88% over the past week, Cohance Lifesciences Ltd has significantly lagged behind, indicating a stark contrast in performance. The stock's negative return of -22.85% over the past year further emphasizes its underperformance compared to the broader market, which has seen a slight decline of only 0.67%. Additionally, the increase in pledged promoter shares, which now account for 100% of holdings, adds downward pressure in a falling market, contributing to investor concerns. Overall, the combination of poor financial results, high valuations relative to peers, and increased risk from pledged shares are key factors driving the stock's recent decline.